These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18657420)

  • 21. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates.
    Yang J; Chen H; Vlahov IR; Cheng JX; Low PS
    J Pharmacol Exp Ther; 2007 May; 321(2):462-8. PubMed ID: 17289839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.
    Kawano K; Onose E; Hattori Y; Maitani Y
    Mol Pharm; 2009; 6(1):98-104. PubMed ID: 19072653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folate receptor-targeted drugs for cancer and inflammatory diseases.
    Low PS; Antony AC
    Adv Drug Deliv Rev; 2004 Apr; 56(8):1055-8. PubMed ID: 15094205
    [No Abstract]   [Full Text] [Related]  

  • 24. Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3.
    Taft F; Harmrolfs K; Nickeleit I; Heutling A; Kiene M; Malek N; Sasse F; Kirschning A
    Chemistry; 2012 Jan; 18(3):880-6. PubMed ID: 22170289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The folate receptor: what does it promise in tissue-targeted therapeutics?
    Salazar MD; Ratnam M
    Cancer Metastasis Rev; 2007 Mar; 26(1):141-52. PubMed ID: 17333345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folate-targeted drug strategies for the treatment of cancer.
    Leamon CP
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1277-86. PubMed ID: 19037834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretubulysin, a potent and chemically accessible tubulysin precursor from Angiococcus disciformis.
    Ullrich A; Chai Y; Pistorius D; Elnakady YA; Herrmann JE; Weissman KJ; Kazmaier U; Müller R
    Angew Chem Int Ed Engl; 2009; 48(24):4422-5. PubMed ID: 19431172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor detection using folate receptor-targeted imaging agents.
    Sega EI; Low PS
    Cancer Metastasis Rev; 2008 Dec; 27(4):655-64. PubMed ID: 18523731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of oligotuftsin-based branched oligopeptide conjugates for chemotactic drug targeting.
    Mezö G; Láng O; Jakab A; Bai KB; Szabó I; Schlosser G; Láng J; Köhidai L; Hudecz F
    J Pept Sci; 2006 May; 12(5):328-36. PubMed ID: 16245264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Click-to-chelate": in vitro and in vivo comparison of a 99mTc(CO)3-labeled N(tau)-histidine folate derivative with its isostructural, clicked 1,2,3-triazole analogue.
    Mindt TL; Müller C; Melis M; de Jong M; Schibli R
    Bioconjug Chem; 2008 Aug; 19(8):1689-95. PubMed ID: 18646835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
    Singh P; Gupta U; Asthana A; Jain NK
    Bioconjug Chem; 2008 Nov; 19(11):2239-52. PubMed ID: 18950215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stopped-flow kinetic studies of the interaction of bovine folate binding protein (FBP) and folate.
    Christensen U; Holm J; Hansen SI
    Biosci Rep; 2006 Aug; 26(4):291-9. PubMed ID: 17029005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Access to Potent Anticancer Tubulysins and Linker-Functionalized Payloads Via an All-On-Resin Strategy.
    Ricardo MG; Llanes D; Rennert R; Jänicke P; Rivera DG; Wessjohann LA
    Chemistry; 2024 Jul; 30(42):e202401943. PubMed ID: 38771268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates.
    Vlahov IR; Santhapuram HK; You F; Wang Y; Kleindl PJ; Hahn SJ; Vaughn JF; Reno DS; Leamon CP
    J Org Chem; 2010 Jun; 75(11):3685-91. PubMed ID: 20423159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.
    Leamon CP; Reddy JA; Dorton R; Bloomfield A; Emsweller K; Parker N; Westrick E
    J Pharmacol Exp Ther; 2008 Dec; 327(3):918-25. PubMed ID: 18791065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schizophyllan-folate conjugate as a new non-cytotoxic and cancer-targeted antisense carrier.
    Hasegawa T; Fujisawa T; Haraguchi S; Numata M; Karinaga R; Kimura T; Okumura S; Sakurai K; Shinkai S
    Bioorg Med Chem Lett; 2005 Jan; 15(2):327-30. PubMed ID: 15603948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a folate-PPE conjugate to image cancer cells in vitro.
    Kim IB; Shin H; Garcia AJ; Bunz UH
    Bioconjug Chem; 2007; 18(3):815-20. PubMed ID: 17373773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of cyclic peptides and cyclic proteins via ligation of peptide hydrazides.
    Zheng JS; Tang S; Guo Y; Chang HN; Liu L
    Chembiochem; 2012 Mar; 13(4):542-6. PubMed ID: 22302623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved Total Synthesis of Tubulysins and Design, Synthesis, and Biological Evaluation of New Tubulysins with Highly Potent Cytotoxicities against Cancer Cells as Potential Payloads for Antibody-Drug Conjugates.
    Nicolaou KC; Erande RD; Yin J; Vourloumis D; Aujay M; Sandoval J; Munneke S; Gavrilyuk J
    J Am Chem Soc; 2018 Mar; 140(10):3690-3711. PubMed ID: 29381062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comments on the article by Christensen U, Holm J and Hansen SI (2006) Bioscience Reports 26:291-299.
    Nygren-Babol L
    Biosci Rep; 2007 Dec; 27(6):413-4; author reply 414-7. PubMed ID: 17932740
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.